Bernardoni, Fabio
Tam, Friederike
Poitz, David M.
Hellerhoff, Inger http://orcid.org/0000-0002-6152-5834
Arold, Dominic
Geisler, Daniel
Lemme, Frances
Keeler, Johanna
Weidner, Kerstin http://orcid.org/0009-0007-9140-4068
Pariante, Carmine http://orcid.org/0000-0002-9132-5091
Roessner, Veit
King, Joseph A.
Ehrlich, Stefan
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung (2019_A118)
B. Braun-Stiftung
Marga und Walter Boll-Stiftung
Medical Faculty of Technical University Dresden
Deutsche Forschungsgemeinschaft (EH 367/5-1, EH 367/7-1 and SFB 940)
Ingvild Goetz Philantropy, Swiss Anorexia Nervosa Foundation
Article History
Received: 16 October 2023
Revised: 10 February 2024
Accepted: 19 February 2024
First Online: 9 March 2024
Competing interests
: VR has received payment for consulting and writing activities from Eli Lilly and Co., Novartis and Shire Pharmaceuticals/Takeda, lecture honoraria from Eli Lilly and Co., Novartis, Shire Pharmaceuticals/Takeda, and Medice Pharma, and support for research from Shire Pharmaceuticals/Takeda and Novartis. VR has carried out (and is currently carrying out) clinical trials in cooperation with Novartis, Shire Pharmaceuticals/Takeda and Otsuka. VR has no financial relationship with the organizations that sponsored the research. All other authors have nothing to disclose.